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Background: Although it has been suggested that schoolchildren vaccination reduces influenza morbidity and
mortality in the community, it is unknown whether geographical heterogeneity would affect vaccine effectiveness.
Methods: A 3-year prospective, non-randomized sero-epidemiological study was conducted during 2008–2011 by
recruiting schoolchildren from both urban and rural areas. Respective totals of 124, 206, and 176 households were
recruited and their household contacts were followed. Serum samples were collected pre-vaccination, one-month
post-vaccination and post-season from children and household contacts for hemagglutination inhibition (HI) assay.
A multivariate logistic model implemented with generalized estimation equations (GEE) was fitted with morbidity or
a four-fold increase in HI titer of the household contacts for two consecutive sera as the dependent variable; with
geographical location, vaccination status of each household and previous vaccination history as predictor variables.
Results: Although our results show no significant reduction in the proportion of infection or clinical morbidity
among household contacts, a higher risk of infection, indicated by odds ratio > 1, was consistently observed among
household children contacts from the un-vaccinated households after adjusting for confounding variables. Interestingly,
a statistically significant lower risk of infection was observed among household adult contacts from rural area
when compared to those from urban area (OR = 0.89; 95% CI: 0.82-0.97 for Year 2 and OR = 0.85; 95% CI: 0.75-0.96
for Year 3).
Conclusions: A significant difference in the risk of influenza infection among household adults due to
geographical heterogeneity, independent of schoolchildren vaccination status, was revealed in this study. Its
impact on vaccine effectiveness requires further study.
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Influenza is a major cause of morbidity and mortality,
resulting in an estimated 3–5 million cases of severe influ-
enza illness annually [1]. Although older adults have the
highest influenza-related mortality, children who have
contracted influenza infection experience substantial mor-
bidity, resulting in absence from school, extra working
days for parents and increased health care costs from pur-
chasing antibiotics [2-4]. Additionally, children attending
day-care centers and elementary schools have long been
identified as the major causes of influenza virus transmis-
sion in the community since they can shed greater
amounts of virus for longer periods of time [5-8]. In fact,* Correspondence: dychao@nchu.edu.tw
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is the presence of children [6]. Focusing efforts for influ-
enza vaccination on school-aged children may therefore
be an effective and practical method for reducing the bur-
den of influenza in the community. Since 2008, the Advis-
ory Committee on Immunization Practices (ACIP) of the
Centers for Disease Control and Prevention (CDC) in the
U.S.A. expanded universal influenza vaccination recom-
mendations to all children aged 0.5-18 years [9].
A systematic review suggested that although evidence
exists that vaccinating healthy children has the potential
of reducing the effect of influenza transmission within
households and community, further data are needed be-
cause of limitations in study design, varied vaccination
policy implemented by different countries and prior ex-
perience of receiving vaccination which make the benefitstd. This is an Open Access article distributed under the terms of the Creative
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more, recent studies from 2009 pandemic H1N1 (pH1N1)
outbreaks suggest that transmissions of influenza virus
were spatially heterogeneous [15]. So far, it is unknown
whether spatially heterogeneous transmission of influenza
virus affects the infection rate and vaccine effectiveness
within households.
Since 2007, the government in Taiwan has implemented
a free vaccination program through which all schoolchil-
dren in grades 1–4 receive a free annual trivalent influenza
vaccination (TIV), which later expanded to grades 1–6
after 2010: a single dose from commercially-available TIV
containing 0.5-mL of 15ug HA of the H1N1, H3N2 and B
antigen would be administered through a school-based
delivery program. From 2008–2011, we recruited elemen-
tary schoolchildren from both urban and rural areas dur-
ing three consecutive influenza seasons and followed up
three different cohorts of their household contacts. The
current non-randomized study offered a unique opportun-
ity to evaluate (1) the effect of vaccinating school-aged
children on reducing virus transmission and influenza re-
lated morbidity among their household contacts, and (2)
the influence of geographical location on acquiring influ-
enza infection among the household contacts.
Methods
Subject enrollment and serological specimens
During three consecutive influenza seasons from 2008 to
2011, a prospective non-randomized sero-epidemiological
study was conducted by the influenza research group at
National Chung-Hsing University (NCHU) and China
Medical University (CMU) to investigate household
transmission and vaccine effectiveness. Students from
two urban (Taichung City) elementary schools and four
rural (Nantou County) schools in central Taiwan were
recruited for this three-year study starting in the fall of
2008. Taichung city is the largest urban city in central
Taiwan with a population of more than 1 million and
has a highly developed socioeconomic structure. The
two schools selected were located respectively in the
North and Central districts of the city, with approxi-
mately 140 thousand total residents. The nearby Nantou
County, which has a total land size approximately 25
times larger than that of Taipei City, is the second lar-
gest county and the only landlocked county on the is-
land of Taiwan with a population of over 500 thousand,
and is comparatively less developed socioeconomically.
The four schools in Nantou County were selected pur-
posely from four different administrative districts in the
county; namely, Nantou City and Tsaotun Township
each with around 100 thousand residents, and the rural
townships of, Mingjian, and Guoshing with 40 and 20
thousand residents, respectively. Since the study proto-
col involved intensive visiting and blood-drawing, allchildren from the selected schools of grades 1–4 during
the first and second study year and grades 1–6 during
the third study year were given a detailed description of
the study protocol and a returned slip was included to
acknowledge if they were willing to participate in the
study voluntarily. Each successive year, some families
dropped out and additional volunteer subjects were re-
cruited. Family members of the school-aged children
were also recruited to join the study to further under-
stand vaccine effectiveness in preventing household
transmissions of seasonal influenza viruses. The serum
samples including pre-vaccination (collected between
September and October), one month post-vaccination
(collected between November and January) and post-
season (collected between April and June) were taken
from children participants by trained nurses, except
during the 2008–2009 season when only sera from post-
vaccination and post-season periods were taken as shown
in Figure 1. Since TIV was not free for household adult
contacts unless they were aged greater than 65 years and
the proportion of TIV vaccination was less than 0.1%, sera
were taken from adult contacts only during pre- and post-
vaccination during the three consecutive seasons. All sub-
jects gave informed consent and the study was approved
by the Medical Ethics Committee of China Medical Uni-
versity (DMR96-IRB-216). The study protocol based on
laboratory data was established to assess the serological
responses by including the paired sera drawn from two
consecutive time periods, in order to define immune re-
sponse before and after vaccination or before vaccination
and post-season among household contacts. The obtained
sera were evaluated for antibody titers by measuring a
hemagglutination inhibition (HI) assay following the
standard protocol by the World Health Organization
(WHO) using the contemporary vaccine and wild-type
strains of influenza viruses as described in the laboratory
methods section below.
Data collection
All study subjects including children participants and
household contacts were assessed for signs and symp-
toms of influenza throughout the follow-up period, de-
fined by the start date (>1 laboratory-confirmed influenza
cases in 2 consecutive weeks from sentinel sites) and ter-
mination date (no laboratory-confirmed influenza cases
for 2 consecutive weeks from sentinel sites) based on the
influenza surveillance network coordinated by Taiwan-
CDC which covers approximately 75% of the basic
administrative units of Taiwan (cities or districts) and
routinely collects clinical specimens [16,17]. The aver-
age influenza virus isolation rates per month during
three consecutive seasons were shown in Figure 1. Dur-
ing each influenza season, two questionnaires were also
administered by trained interviewers regarding basic
Figure 1 Timeframe of TIV vaccination, blood collection as well as influenza virus isolation rates from 2008 to 2011.
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a seasonal influenza vaccination had been received in
the past and present years. Information regarding co-
morbidities including cardiovascular disease, hyperten-
sion, or diabetes mellitus was also taken from the adults
in the family. Bi-weekly clinical symptom reviews were
carried out using a standardized questionnaire via a
telephone interview between October and June. Partici-
pants were asked to report any newly experienced fe-
brile respiratory symptoms, including fevers (≥38°C),
sore throats, cough, nasal congestion, headache, sinus
problems, muscle aches, fatigue, ear ache or infection or
chills during the influenza season. The overall comple-
tion rate for the questionnaires was more than 90%.
Laboratory methods
Antibody titers were measured using HI assay which ad-
hered to the WHO protocol [18,19]. In brief, serum sam-
ples were pre-treated with receptor destroying enzyme
(RDE, Deka Seriken Co Ltd, Tokyo, Japan) in 1:4 ratio at
37°C for 16 hours, followed by another 30 minutes at 56°C
and then an equal volume of 1.6% trisodium citrate was
added for enzyme inactivation. The different strains of
influenza viruses used in this study were first prepared
from the culture supernatants of infected Madin-Darby
canine kidney (MDCK) cells. Twenty-five microliters
(μl) (4 hemagglutination units, HA) of influenza virus
were incubated at room temperature for one hour with
an equal volume of RDE-treated serum in a V-shape 96-
well microtiter plate. After incubation, 25 μl of 1% (vol/
vol) chicken red blood cells was added to each well.
Hemagglutination inhibition was read after 30 minutes.To evaluate asymptomatic infection, influenza viruses
from the contemporary vaccine and wild-type strains
which represented more than 80% of circulating viruses
during the three consecutive influenza seasons were used.
Details are listed in Table 1. For the HI assay, serum
samples were tested with an initial dilution of 1:10 and a
final dilution of 1:10,240 and the titers were expressed
as the reciprocal of the highest dilution of serum where
hemagglutination was prevented. Samples with dilution
higher than 10,240 where hemagglutination was pre-
vented were repeated to obtain the final HI titers. Sam-
ples that were negative by HI were assigned a titer of 1:5
for computational purposes in obtaining a geometric
mean titer (GMT) or seroconversion rate. We defined
seroconversion as a four-fold or greater rise of HI anti-
body titers to influenza A (H1N1), A (H3N2) and B to
assess serological evidence of viral infection among
household contacts. In this study, we excluded house-
hold contacts who had TIV vaccination during the influ-
enza seasons in the analysis to avoid false classification.
This allows us to use a four-fold increase in the sera be-
tween pre- and post-season as a surrogate marker for
viral infection, and compare the likelihood of infection
among household contacts between households of dif-
ferent vaccination statuses as later described in the stat-
istical analysis section.
Statistical analysis
Vaccination status of each household was categorized as
‘complete’, ‘partial’ or ‘non-vaccination’ based on the vac-
cination status of its occupying school-aged child/chil-
dren (named as participants). If all participants in the
Table 1 The contemporary vaccine and wild-type strains circulated during the three consecutive influenza seasons
used in this study




H3N2 A/Brisbane/10/2007 A/Brisbane/10/2007 A/Perth/16/2009





H3N2 A/Taiwan/736/2008 A/Taiwan/480/2008 A/Taiwan/3869/2010
A/Taiwan/480/2008 A/Taiwan/736/2008 A/Taiwan/3814/2011
A/Taiwan/3982/2009
flu B B/Taiwan/29/2008(Y) B/Taiwan/5908/2009(V) B/Taiwan/3591/2010(V)
B/Taiwan/5806/2011(Y)
1Y refer to Yamagada lineage and V refer to Victoria lineage.
2pdmH1N12009: pandemic H1N1 in 2009.
Chao et al. BMC Infectious Diseases 2014, 14:369 Page 4 of 12
http://www.biomedcentral.com/1471-2334/14/369household received or did not receive TIV during the
season, the household was classified as ‘complete’ or ‘un-
vaccination’, respectively. If only some of the participants
from the household received TIV during the season, the
household was classified as ‘partial’. To estimate vaccine
effectiveness in preventing respiratory illness or infection
among household contacts, a logistic model was fitted
with the illness status or four-fold increase of HI titer dur-
ing two consecutive sera of the household contacts as the
dependent variable and the vaccination status of each
household as the predictor variable. Generalized estima-
tion equations (GEE) method was used to account for
correlation among members of the same household. We
tested the hypothesis that there was no difference in the
rate of respiratory illnesses or related infection among
the household contacts of completely vaccinated, par-
tially vaccinated and un-vaccinated households. All stat-
istical analyses were conducted using SAS (release 9.2,
SAS Institute) software. A p-value <0.05 was considered
statistically significant.
Results
Subject recruitment and demographics
Figure 2 describes the numbers of participants and house-
hold contacts recruited in this study during the three
consecutive years and the final numbers entered for
statistical analysis. Except for the first year, there was
more than one school-aged child included in the study
from each household.
For households considered in the final analysis, we
stratified them into ‘complete’, ‘partial’ and ‘un-vaccinated’
according to the immunization status of the participantsfrom each household as previously described. Table 2
shows the basic demographics of participants and house-
hold contacts from three consecutive seasons. The house-
hold sizes were about the same across all three
consecutive seasons - the partially-immunized households
were slightly larger but not significantly different from the
un-vaccinated or completely-vaccinated households. A
higher proportion of recruited participants from the urban
area (Taichung) did not receive TIV (TIV(−) families) ex-
cept in Year 2 (51% from TIV(+) vs 30% from TIV(−) and
43% from partial TIV families), probably due to the occur-
rence of pandemic H1N1 (pH1N1) in 2009.
For children participants from each household, no
gender difference was found during all three years.
However, it was found that during Years 1 and 3, chil-
dren participants who received TIV vaccination were
slightly younger compared to those who did not. For
household contacts, a significantly higher proportion of
young contacts (age less than 18 years) was found in un-
vaccinated (23%) and partially-vaccinated (25%) groups
than from the completely-vaccinated group (11%) during
the second influenza season (p < 0.05). A significantly
higher proportion of household contacts who received
TIV during the previous season was also found in
‘complete’ and ‘partial’ vaccination households than from
‘un-vaccination’ households during the first and second
year of study (p < 0.05) (Table 2).
Immune response and vaccine efficacy among
schoolchildren participants
Table 3 shows the antibody titers from the schoolchil-
dren participants pre- and post-vaccination during three
Figure 2 Flow chart of participant recruitment for all three years.
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antibody titer of post-vaccination sera in participants
who received TIV vaccination, compared to the titer in
participants without receiving TIV, was observed during
Year 1 and 3. Meanwhile, significantly higher immune
responses, including GMT and proportion of HI equal
to or greater than 40, were observed among participants
receiving TIV than those without (Table 3). Higher pro-
portions of participants with 4-fold increase of antibody
titer were also observed among the group receiving TIV
than the group without (51% vs 16% for H1N1 and 16%
vs 0% for B antigens). No difference in antibody titers
was observed between TIV(+) and TIV(−) participants
in the post-season sera for all three study years.
Since pH1N1 circulated before and during the second
influenza year, TIV vaccine was delivered one month
ahead of pH1N1 vaccination. We further divided the
participants from Year 2 with or without receiving TIV
into four groups based on their status of receiving
pH1N1 vaccination. As shown in Table 4, a significantly
higher proportion of participants having HI titer greater
than or equal to 40 in the groups receiving the pH1N1
vaccine was observed than in the group without receiv-
ing the pH1N1 vaccine, particularly among the groups
receiving the pH1N1 but not TIV vaccine (p < 0.05).
Similar results were observed when comparing GMT ti-
ters between two groups. Interestingly, higher antibody
titers against seasonal influenza strains including H1,
H3 and B were observed in children who received the
pH1N1 vaccine than in children without the pH1N1
vaccine regardless of their TIV history (Table 4).Effectiveness of vaccination of schoolchildren in reducing
illness or serologically proven infection among household
contacts
Previous studies suggested that schoolchildren vacci-
nated with TIV could reduce household and community
transmission of influenza virus [10-14]. Our results did
not detect significant reduction in the proportion of in-
fection or clinical morbidity among contacts of the
households with complete TIV vaccination compared to
those with partial or no vaccination (Table 5). Also, we
further divided the household based on the status of re-
ceiving TIV or pH1N1 vaccines during the 2009–2010
influenza season due to the pH1N1 epidemic. Because of
the low numbers of the households did not receive the
pH1N1 vaccine, infection rates of contacts from Year 2
were removed. Higher infection rates (38% of type H3
and 84% of any type) were observed among household
adult contacts from families receiving both TIV and
pH1N1 vaccines than from families not receiving TIV
(26% of type H3 and 76% of any type) with statistical sig-
nificance (p < 0.05) (Table 5). Similar results were ob-
served among household children contacts.
To further investigate if the proportion of serological
infection or clinical morbidity of household contacts
was associated with other confounding variables, multi-
variate analysis using GEE was implemented to adjust
for variables including underlying diseases, household
size, residential location, TIV during the previous year,
the status of household receiving TIV. The results were
shown in Table 6. Gender of household contacts was
not included due to the lack of difference shown
Table 2 Demographic characteristics of trivalent influenza vaccine (TIV) completed, partial and non-vaccinated
households during the three consecutive years of influenza seasons (2008–2011)
1st Year 2nd Year 3rd Year
TIV(−) TIV(+) p TIV(−) Partial TIV TIV(+) p TIV(−) Partial TIV TIV(+) p
No of household
Household size# 3.28 3.45 4.2 7.46 3.84 3.76 7.50 4.12
(3.00,3.58) (3.18,3.72) (3.83,4.64) (6.51,8.40) (3.35,4.34) (3.15,4.36) (6.06,8.94) (3.70,4.54)
Location of residence
Taichung 28(0.47) 22(0.38) 34(0.30) 15(0.43) 29(0.51) * 20(0.49) 9(0.45) 35(0.30) *
Nantou 31(0.53) 43(0.62) 80(0.70) 20(0.57) 28(0.49) 21(0.51) 11(0.55) 80(0.70)
Participants
Gender
Male 31(0.53) 34(0.52) 71(0.52) 33(0.47) 31(0.48) 19(0.41) 21(0.49) 75(0.54)
Female 28(0.47) 31(0.48) 66(0.48) 37(0.53) 33(0.52) 27(0.59) 22(0.51) 65(0.46)
Age (average years)# 9.24 8.00 * 9.39 9.20 9.11 10.80 9.65 9.66 *
(8.83,9.64) (7.64,8.36) (9.10,9.68) (8.75,9.65) (8.76,9.45) (10.24,11.37) (9.04,10.26) (9.39,9.94)
Household contacts
Gender
Male 60(0.44) 63(0.40) 152(0.44) 78(0.44) 55(0.40) 40(0.37) 45(0.42) 142(0.44)
Female 75(0.56) 96(0.60) 192(0.56) 100(0.56) 84(0.60) 68(0.63) 61(0.58) 181(0.56)
Age
<18 37(0.27) 43(0.27) 80(0.23) 45(0.25) 15(0.11) * 31(0.29) 32(0.30) 74(0.23)
≥18 98(0.73) 116(0.73) 264(0.77) 133(0.75) 124(0.89) 77(0.71) 74(0.70) 249(0.77)
Age (average years)# 34.35 33.51 36.84 36.19 40.22 35.47 31.81 36.49
(31.46,37.24) (30.82,36.20) (34.91,38.77) (33.51,38.87) (37.58,42.85) (31.79,39.16) (28.63,34.99) (34.55,38.43)
Vaccinated in previous year
Yes 9(0.07) 29(0.18) 7(0.02) 21(0.12) 23(0.17) * 16(0.15) 18(0.17) 68(0.21)
No 126(0.93) 130(0.82) 337(0.98) 157(0.88) 116(0.83) 92(0.85) 88(0.83) 255(0.79)
*p < 0.05.
#Numbers in brackets are 95 % confidence interval calculated by GEE method.
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mostly insignificant, a higher risk of infection, indicated by
odds ratio greater than 1, was consistently observed among
household children contacts from the un-vaccinated
households. During the first year, a significantly higher
risk of infection and clinical morbidity was observed
among children contacts from un-vaccinated households
than from complete vaccinated households (p < 0.05). No
statistical significance for risk of infection and morbidity
was observed among household adult contacts and odds
ratios were not consistently greater than 1.
Interestingly, after adjusting for households with or
without TIV vaccination, lower risk of infection was ob-
served among household adult contacts from the rural
residential area compared to those from the urban area
(OR = 0.89; 95% CI: 0.82-0.97 for Year 2 and OR = 0.85;
95% CI: 0.75-0.96 for Year 3) (Table 6). Similar results
were also observed among adult contacts for infection
with clinical symptoms.Discussion
Although vaccine recommendations have been grad-
ually expanded to include all persons ≥6 months of age,
the vaccination strategy specifically targeting schoolchil-
dren to reduce community-wide or household transmis-
sion of seasonal influenza is still debatable [20-22].
Recent school-based and community cluster-randomized
control trials suggest that the vaccination of schoolchil-
dren can reduce influenza-related morbidity and mortality
among non-immunized contacts within households [14]
and in the community [10-13]. Consistent with previous
reports, secondary infection risks within households were
highest among young contacts [23-25]. In our current
study, although no statistically significant reduction of
serological-confirmed infection or clinical morbidity
among the vaccinated household contacts was observed
during three consecutive seasons, a consistent trend
was observed among household children contacts from
un-vaccinated households having a greater risk of infection
Table 3 Hemagglutination antibody titers of schoolchildren participant sera obtained before, after vaccination and post-season during three consecutive years
1st Year 2nd Year 3rd Year
TIV(−) TIV(+) P TIV(−) TIV(+) P TIV(−) TIV(+) P
N = 59 N = 65 N = 172 N = 99 N = 67 N = 162
Pre-vaccination
HI-titer≧40
H1N1 - - 155(0.90) 91(0.92) 45(0.67) 124(0.77)
H3N2 - - 142(0.83) 77(0.78) 17(0.25) 58(0.36)
B - - 44(0.26) 26(0.26) 49(0.73) 104(0.64) *
GMT#
H1N1 - - 263.78(211.80,315.75) 412.83(246.23,579.42) * 82.76(60.50,105.02) 89.38(75.14,103.62)
H3N2 - - 210.26(168.06,252.46) 245.91(166.90,324.92) 52.54(20.37,84.70) 85.40(57.74,113.06)
B - - 25.76(21.17,30.34) 30.81(22.25,39.36) 69.18(53.71,84.65) 75.43(54.95,95.92)
Post-vaccination
HI-titer≧40
H1N1 33(0.56) 60(0.92) * 112(0.65) 61(0.62) 37(0.55) 132(0.81) *
H3N2 51(0.86) 59(0.91) 114(0.66) 61(0.62) 6(0.09) 49(0.30) *
B 26(0.44) 43(0.66) * 72(0.42) 39(0.39) 23(0.34) 73(0.45)
GMT#
H1N1 161.80(91.12,232.48) 422.77(232.82,612.71) * 408.08(306.32,509.84) 324.14(245.96,402.32) 97.76(19.45,176.07) 121.33(100.60,142.06)
H3N2 353.93(253.05,454.81) 411.41(312.73,510.09) 487.59(407.64,567.53) 455.61(368.75,542.46) 20.82(12.91,28.73) 61.82(41.07,82.57) *
B 115.74(67.21,164.28) 114.24(83.34,145.14) 46.48(38.09,54.87) 48.59(36.73,60.45) 33.13(24.06,42.21) 44.26(33.37,55.15)
4-Fold increase (Post vs Pre-vaccination)
H1N1 - - 39(0.23) 17(0.17) 11(0.16) 82(0.51) *
H3N2 - - 60(0.35) 36(0.36) 3(0.04) 15(0.09)
B - - 62(0.36) 31(0.31) 0(0.00) 26(0.16) *
Post-season
HI-titer≧40
H1N1 40(0.68) 60(0.68) 154(0.90) 89(0.90) 45(0.67) 116(0.72)
H3N2 48(0.82) 59(0.82) 163(0.95) 95(0.96) 28(0.42) 75(0.46)
B 24(0.40) 43(0.40) 167(0.97) 93(0.94) 26(0.39) 68(0.42)
GMT# - -
H1N1 129.26(71.17,187.34) 157.46(68.66,246.25) 570.61(497.40,643.82) 503.08(410.42,595.74) 132.69(87.48,177.89) 90.52(77.27,103.78) *
H3N2 272.46(159.43,385.48) 209.03(120.55,297.52) 319.04(269.30,368.79) 390.61(316.43,464.78) 99.63(34.88,164.38) 165.77(110.13,221.41)
B 40.43(28.70,52.15) 55.53(38.39,72.67) 23.46(20.42,26.50) 24.70(20.09,29.31) 31.34(22.69,40.00) 37.87(28.82,46.92)
*p < 0.05.




















Table 4 Hemagglutination antibody titers during the second influenza season based on TIV or pH1N1 vaccination
status of schoolchildren participants
Participants
(schoolchildren)
TIV(−) N = 172 TIV(+) N = 99
pH1N1(−) N = 17 pH1N1(+) N = 155 P pH1N1(−) N = 6 pH1N1(+) N = 93 P
Pre-vaccination
HI-titer≧40
pH1N1 11(0.65) 112(0.72) 4(0.67) 68(0.73)
H1N1 14(0.82) 141(0.91) 4(0.67) 87(0.94)
H3N2 13(0.77) 129(0.83) 5(0.83) 72(0.77) *
B 5(0.29) 39(0.25) 2(0.33) 24(0.26)
GMT#
pH1N1 48.24(28.72,67.75) 56.77(49.45,64.10) 65.00(7.23,122.77) 57.58(48.92,66.24)
H1N1 162.94(79.96,245.92) 274.84(217.97,331.71) * 433.33(−64.89,931.55) 411.51(235.43,587.58)
H3N2 207.06(42.89,371.22) 210.61(166.67,254.56) 107.50(40.65,174.35) 254.84(171.02,338.65) *
B 17.65(9.77,25.52) 26.65(21.64,31.65) * 66.67(−64.31,197.64) 28.49(21.90,35.09)
Post-vaccination
HI-titer≧40
pH1N1 2(0.12) 101(0.65) * 2(0.33) 52(0.56) *
H1N1 4(0.24) 108(0.70) * 3(0.50) 58(0.62) *
H3N2 4(0.24) 110(0.71) * 4(0.67) 57(0.61)
B 2(0.12) 70(0.45) * 3(0.50) 36(0.39)
GMT#
H1N1_p 49.41(30.22,68.60) 216.65(167.73,265.56) * 84.17(14.68,153.65) 228.60(154.87,302.33) *
H1N1 202.94(40.19,365.69) 430.58(319.28,541.88) * 270.00(45.61,494.39) 327.63(245.00,410.27)
H3N2 220.00(58.35,381.65) 516.94(430.86,603.01) * 213.33(−9.85,436.51) 471.24(380.18,562.29) *
B 23.24(10.48,35.99) 49.03(39.89,58.17) * 148.33(−3.62,300.29) 42.15(33.09,51.21)
*p < 0.05.
#numbers in brackets are 95% confidence interval calculated by GEE method.
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http://www.biomedcentral.com/1471-2334/14/369or combined clinical morbidity (odds ratio greater than 1)
after adjusting for confounding variables. During Year 3,
odds ratio less than 1 was observed among children con-
tacts from partial-immunization households, which was
probably due to the small sample size. In contrast, no con-
sistent trend was observed among household adult con-
tacts since the resulting odds ratios were not always
greater than 1. One reason could be that household adults
usually acquire infection from the community [15,26]. In
particular, we observed a higher rate of infection in adults
living in urban areas than those living in rural areas. There-
fore, vaccinating schoolchildren may not provide sufficient
protection to the household adult contacts living in urban
cities. Since we didn’t measure risk of infection conditioned
on the level of exposure, only overall risk was considered
in this study by adjusting the confounding variables using
GEE methods and the potential bias of household vaccin-
ation status might affect the risk of exposure cannot be
ruled out; ie. the household contact from unvaccinated
households tended to be more careful to prevent having in-
fluenza infection. However, higher risk of infection amonghousehold adult contacts was observed in the urban area
with lower vaccination rate, than rural area with higher
vaccination rate (Tables 2 and 6). In the future, large clinical
trials considering the transmission intensity in different
geographic locations will be needed to assess the benefits
of the schoolchildren vaccination policy on the household
contacts and community.
Observational studies to assess vaccine effectiveness
have become a standard way of routinely evaluating
how well influenza vaccines protect population groups
in countries implementing influenza vaccination pro-
grams [27-30]. These studies usually utilize a sensitive
and specific laboratory method such as virus isolation
or reverse-transcriptase polymerase chain reaction (RT-
PCR) to confirm illness as influenza. These methods
may miss a case if administered too early (e.g., during
the incubation period) or too late (e.g., after the infec-
tious period) in the disease course. Since many influ-
enza cases are asymptomatic, identifying every case
would necessitate serially screening the entire study
population throughout the influenza season, which
Table 5 Proportions of infection or clinical morbidity among household contacts of children and adults among three
TIV vaccination status groups during the three consecutive influenza seasons
1st Year 2nd Year 3rd Year
Children, Number (proportion) TIV(−) TIV(+) P TIV(−) Partial TIV TIV(+) P TIV(−) Partial TIV TIV(+) P
N = 37 N = 43 N = 72 N = 38 N = 14 N = 31 N = 32 N = 74
4-fold increase
H1N1 6(0.16) 6(0.14) 29(0.40) 10(0.26) 3(0.21) 13(0.42) 12(0.38) 31(0.42)
H3N2 4(0.11) 14(0.33) 30(0.42) 17(0.45) 4(0.29) 11(0.35) 6(0.19) 26(0.35)
B 4(0.11) 3(0.07) 35(0.49) 17(0.45) 7(0.50) 6(0.19) 14(0.44) 18(0.24)
pH1N1 - - 55(0.76) 27(0.71) 13(0.93) - - -
Any 4-fold increase 14(0.38) 20(0.47) 44(0.61) 23(0.61) 7(0.50) 22(0.71) 21(0.66) 52(0.70)
Symptoms
Any 17(0.46) 29(0.67) 36(0.50) 22(0.58) 9(0.64) 19(0.61) 13(0.41) 37(0.50)
Fever 5(0.14) 14(0.33) 7(0.10) 1(0.03) 1(0.07) 3(0.10) 6(0.19) 9(0.12)
Fever plus any two symptoms 3(0.08) 10(0.23) 4(0.06) 0(0.00) 0(0.00) 1(0.03) 4(0.13) 7(0.09)
Any 4-fold increase plus any symptoms 5(0.14) 15(0.35) * 24(0.33) 13(0.34) 5(0.36) 27(0.87) 24(0.75) 62(0.84)
Adults, Number (proportion) TIV(−) TIV(+) P TIV(−) Partial TIV TIV(+) P TIV(−) Partial TIV TIV(+) P
N = 98 N = 116 N = 222 N = 111 N = 109 N = 77 N = 74 N = 249
Any 4-fold increase
H1N1 0(0.00) 2(0.02) 70(0.32) 46(0.41) 41(0.38) 10(0.13) 19(0.26) 60(0.24)
H3N2 9(0.09) 17(0.15) 57(0.26) 38(0.34) 41(0.38) * 3(0.04) 0(0.00) 6(0.02)
B 5(0.05) 3(0.03) 70(0.32) 45(0.41) 38(0.35) 4(0.05) 6(0.08) 18(0.07)
pH1N1 - - 109(0.49) 57(0.51) 55(0.50) - - -
Any 4-fold increase 14(0.14) 20(0.17) 135(0.61) 74(0.67) 75(0.69) 11(0.14) 20(0.27) 64(0.26)
Symptoms
Any 43(0.44) 52(0.45) 55(0.25) 34(0.31) 39(0.36) * 30(0.39) 31(0.42) 105(0.42)
Fever 9(0.09) 5(0.04) 1(0.00) 4(0.04) 2(0.02) 2(0.03) 1(0.01) 7(0.03)
Fever plus any two symptoms 0(0.00) 1(0.01) 0(0.00) 0(0.00) 0(0.00) 1(0.01) 0(0.00) 5(0.02)
Any 4-fold increase plus any symptoms 7(0.07) 7(0.06) 39(0.18) 24(0.22) 24(0.22) 38(0.49) 42(0.57) 131(0.53)
*P < 0.05.
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http://www.biomedcentral.com/1471-2334/14/369currently would be prohibitively expensive and oper-
ationally challenging. The advantage of using serological
four-fold increase of HI titers in this study as a surrogate
marker of infection was that the true infection rate could
be estimated. To measure the true infections among
household contacts, all contacts having TIV vaccination
records during the contemporary influenza season were
pre-excluded from the analysis. The possibility of a de-
layed rising of antibody titer post-infection, resulting in
mis-classification of infection status among different
groups, was also considered. The median durations of sera
withdrawn were equivalent among household contacts
from households with different vaccination statuses. As
shown in Table 5, the infection rates from serological re-
sults among the household contacts were much higher
than those previously published in studies using RT-PCR
to estimate infection [12,22,31]; however, consistent with
our previous publication [32]. All virus strains used in this
study were originated from human, instead of avian-origin, and the negative control was used all the time dur-
ing performing the assay. Although guinea pig RBC is
strongly suggested for HI assay, the potential bias using
chicken RBC in this study will be minimal but cannot be
completely excluded [33,34]. However, the disadvantage of
using serological four-fold increase of HI titers as an infec-
tion marker was that if the true benefits of the schoolchil-
dren vaccinating policy is to prevent clinical illness instead
of infection, this method under-estimated the vaccination
effectiveness. Therefore, no statistically significant reduc-
tion of serological-confirmed infection among the vacci-
nated household contacts was observed during three
consecutive seasons in this study due to the high infection
rate by influenza virus. The unexpected findings of high
infection rate and low effectiveness of household contacts
require further study.
Measuring serologically confirmed infection allowed us
to compare the transmission and infection of influenza
virus in different geographical locations. Our multivariate
Table 6 Multivariate logistic regression on proportion of infection or plus clinical morbidity among household contacts
during three consecutive influenza seasons
Any 4-fold increase$ p Any 4-fold increase plus any symptoms$ p
Children
1st Year Rural v.s urban 1.03 (0.79,1.34) 0.835 0.93 (0.76,1.13) 0.458
Household size 0.97 (0.85,1.11) 0.692 0.96 (0.87,1.06) 0.385
TIV previous year 0.72 (0.42,1.22) 0.221 0.97 (0.76,1.25) 0.831
TIV (−) v.s (+) 1.26 (0.93,1.70) 0.139 1.27 (1.03,1.56) 0.024*
2nd Year Rural v.s urban 0.95 (0.79,1.13) 0.547 0.93 (0.76,1.14) 0.505
Household size 1.01 (0.81,1.27) 0.901 1.00 (0.79,1.27) 0.997
TIV previous year 0.91 (0.60,1.38) 0.664 1.10 (0.70,1.75) 0.672
TIV (−) v.s (+) 1.08 (0.76,1.52) 0.664 1.03 (0.70,1.52) 0.886
TIV partial v.s (+) 1.09 (0.75,1.58) 0.665 1.06 (0.68,1.66) 0.800
3rd Year Rural v.s urban 1.10 (0.96,1.25) 0.171 1.02 (0.84,1.24) 0.834
Household size 1.03 (0.93,1.13) 0.607 1.07 (0.95,1.21) 0.260
TIV this year 1.03 (0.91,1.16) 0.665 0.94 (0.79,1.11) 0.451
TIV (−) v.s (+) 1.09 (0.96,1.24) 0.184 1.13 (0.92,1.38) 0.249
TIV partial v.s (+) 0.91 (0.76,1.09) 0.306 0.85 (0.66,1.08) 0.186
Adults
1st Year Rural v.s urban 0.98 (0.87,1.21) 0.161 1.02 (0.93,1.12) 0.693
Household size 1.02 (0.97,1.07) 0.444 1.00 (0.97,1.04) 0.806
TIV previous year 1.11 (0.91,1.35) 0.314 0.94 (0.90,0.97) <0.001*
TIV (−) v.s (+) 1.01 (0.91,1.12) 0.878 0.99 (0.92,1.06) 0.726
2nd Year Rural v.s urban 0.89 (0.82,0.97) 0.006* 0.91 (0.84,0.99) 0.024*
Household size 0.89 (0.80,1.00) 0.046* 0.99 (0.90,1.08) 0.762
TIV previous year 0.98 (0.83,1.16) 0.809 1.08 (0.92,1.28) 0.342
TIV (−) v.s (+) 0.95 (0.85,1.06) 0.359 0.98 (0.89,1.08) 0.688
TIV partial v.s (+) 1.07 (0.94,1.23) 0.303 1.02 (0.91,1.16) 0.700
3rd Year Rural v.s urban 0.85 (0.75,0.96) 0.010* 0.87 (0.77,0.99) 0.031*
Household size 1.03 (0.93,1.13) 0.620 1.05 (0.94,1.18) 0.385
TIV previous year 1.08 (0.91,1.30) 0.381 0.96 (0.80,1.14) 0.627
TIV (−) v.s (+) 0.94 (0.81,1.09) 0.423 0.95 (0.82,1.10) 0.476
TIV partial v.s (+) 0.99 (0.83,1.19) 0.919 0.92 (0.75,1.12) 0.402
$Odds ratio (95% confidence interval).
*p < 0.05.
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suggested that a lower risk of acquiring infection was ob-
served among household adult contacts from the rural
residential area than among those from the urban area
with statistical significance (Table 6). Recent studies from
2009 pandemic H1N1 (pH1N1) outbreaks suggested that
the transmissions of influenza virus were spatially hetero-
geneous [15,26]. A different contact profile in different so-
cial settings, social and geographic factors probably shape
the local reproduction number (R0) [35,36]. The crowded-
ness of urban environments facilitates influenza virus
transmission, and adults might acquire infection through
variable contact pathways in the community. As such, thismight compromise the vaccine effectiveness of the school-
children vaccination policy in reducing influenza-related
morbidity and mortality of household contacts, particu-
larly in adults. Designing an optimal mitigation measure-
ment tailored to different geographical locations will help
to control the influenza epidemic or pandemic.
Another interesting finding in our study was that
higher antibody titers against seasonal influenza strains
including H1, H3 and B were observed in children who
received the pH1N1 vaccine than in those who did not.
This observation was independent from whether or not
the children received TIV. Previous studies suggested
that broadly neutralizing antibodies reactive to the
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http://www.biomedcentral.com/1471-2334/14/369conserved stem region of the influenza virus hemagglutinin
(HA) were generated in people infected or vaccinated with
the 2009 pandemic H1N1 strain [37,38]. Additionally,
other studies also suggested that a vigorous antibody re-
sponse to pH1N1 vaccination resulted from the activation
of preexisting memory B cells, which did not only bind to
the stem region but also the head region of HA [39].
Furthermore, cross-reactive T-cell responses can also
contribute to the cross-protection. A larger sample size
will be needed to confirm this observation.
The main limitation of our study relates to the small
sample sizes among subsets of the participants receiving
TIV, which reduced both the statistical power and preci-
sion. Same reason for the attempt of calculating attack
rates within households and compare them among vac-
cinated, partial and non-vaccinated households. Particu-
larly in Year 2, two vaccines (TIV and pH1N1) were
delivered during the same season one month apart. Our
previous study demonstrated that children who received
TIV prior to pH1N1 had a lower sero-conversion rate
than those who received only the pH1N1 vaccine [40].
Whether this was the cause of the higher infection rates
among the household contacts observed in our study, as
shown in Table 5, requires further confirmation. Poten-
tial self-selection bias of study subjects involved in this
study is possible, particularly since more families were
recruited from rural areas than urban areas in this study.
Furthermore, timing of vaccination or period of sera col-
lection coincided with the circulation of influenza vi-
ruses might also affect the determination of status of
infection, particularly during Year 2. Prior immunity of
each individual could also affect the protection level,
data of which was available for this study but appeared
insignificant due to small sample size after stratification.
Conclusions
Although drawing a conclusion from data in this obser-
vational study requires careful interpretation of the re-
sults, due to the possibility of bias of given self-selection
for vaccination, assessing the effectiveness of the school-
children vaccination policy on protection of household
contacts and community would require further research
on geographical heterogeneity of influenza transmission
and infection.
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